EU6.F PDS Biotechnology Corp

Healthcare Biotechnology Frankfurt Exchange
0.9840 EUR
Close of Nov 12, 2026
0.1710 1.59
Market cap
EUR 121M
P/E
-
P/B
3.58x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is EU6.F undervalued?

Graham number

The Graham number of PDS Biotechnology Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PDS Biotechnology Corp fundamental analysis

No fundamental analysis for PDS Biotechnology Corp yet.

PDS Biotechnology Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PDS Biotechnology Corp

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy util…

Full company profile